481.21MMarket Cap-3126P/E (TTM)
5.090High4.520Low1.40MVolume4.980Open5.050Pre Close6.57MTurnover1.83%Turnover RatioLossP/E (Static)105.41MShares8.40052wk High1.83P/B349.12MFloat Cap1.57052wk Low--Dividend TTM76.48MShs Float38.010Historical High--Div YieldTTM11.29%Amplitude1.570Historical Low4.708Avg Price1Lot Size
Annexon Stock Forum
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and mult...
No comment yet